Merck’s Keytruda appeared to outperform GSK’s Jemperli in a key endometrial cancer patient subgroup, suggesting late-stage data revealed Monday during the Society of Gynecologic Oncology 2023 Annual Meeting.
https://www.pharmalive.com/wp-content/uploads/2022/01/Merck-Dives-Deep-into-AI-with-610-Million-Absci-Pact-BioSPace-1-7-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-03-28 09:23:332023-03-28 09:26:03Keytruda maintains edge over GSK’s Jemperli in endometrial cancer
